Background:
Hyperhomocysteinemia, cardiovascular disease (CVD), and malnutrition are common in patients with end-stage renal disease (ESRD). This study was designed to assess possible relationships between total plasma homocysteine (tHcy), nutritional status, and ischemic CVD.
Methods:
We performed a cross-sectional study in 117 unselected patients on maintenance hemodialysis (HD) treatment, among whom there was a high prevalence of malnutrition (56%), as assessed by the subjective global nutritional assessment (SGNA), and a high prevalence of CVD (60%), and prospectively, we followed-up the overall mortality for four years.
Results:
The level of tHcy was elevated in 95% of the HD patients, and that of total plasma cysteine (tCys) was also significantly elevated, while the plasma concentrations of methionine (Met), serine (Ser), and taurine (Tau) were significantly lower than those in healthy controls. The 65 patients who were malnourished according to the SGNA score had significantly lower levels of serum albumin (SAlb), plasma IFG-1 (p-IGF-1), tHcy, tCys, and Met than the 52 patients with normal nutritional status, whereas the levels of Ser, Tau, plasma folate, and vitamin B12 were similar in the two groups. The prevalence of malnutrition was 30% in the 47 patients without CVD and was significantly higher (70%, P < 0.001) in the 70 patients with CVD, who also had lower tHcy, SAlb, plasma IGF-1, serum creatinine (SCr), and blood hemoglobin. The tHcy levels were positively correlated with SAlb, Met, tCys, and SCr. Stepwise, multiple-regression analysis showed that tCys, SAlb, and normalized protein equivalent of nitrogen appearance (nPNA), an indicator of protein intake, were independent predictors of tHcy. The patients with tHcy <24 micromol/L (median value) had a significantly worse four-year survival than those with a higher tHcy (> or =24 micromol/L).
Conclusions:
Our results demonstrate that most of HD patients have grossly elevated tHcy levels, but that the absolute level appears to be dependent on nutritional status, protein intake, and SAlb. The results also suggest that the lower tHcy levels in patients with CVD than in those without CVD may be related to the higher prevalence of malnutrition and hypoalbuminemia in the CVD patients. This is also in accordance with our observation that the patients with lower tHcy had a worse survival rate than those with higher tHcy, considering that malnutrition is a strong risk factor for mortality and that CVD is the most common cause of death in ESRD patients.
Citing Articles
Malnutrition Is an Independent Risk Factor for Low Health-Related Quality of Life Among Centenarians.
Yang S, Wang S, Liu W, Han K, Jia W, Liu M
Front Med (Lausanne). 2021; 8:729928.
PMID: 34631749
PMC: 8498216.
DOI: 10.3389/fmed.2021.729928.
Gut Microbiome, Functional Food, Atherosclerosis, and Vascular Calcifications-Is There a Missing Link?.
Cretoiu D, Ionescu R, Enache R, Cretoiu S, Voinea S
Microorganisms. 2021; 9(9).
PMID: 34576810
PMC: 8472650.
DOI: 10.3390/microorganisms9091913.
Folic Acid and Vitamin B12 Administration in CKD, Why Not?.
Capelli I, Cianciolo G, Gasperoni L, Zappulo F, Tondolo F, Cappuccilli M
Nutrients. 2019; 11(2).
PMID: 30781775
PMC: 6413093.
DOI: 10.3390/nu11020383.
Evaluation of Nutritional Biochemical Parameters in Haemodialysis Patients over a Ten-year Period.
Alfonso A, Castillo R, Gomez Jimenez F, Nunez Negrillo A
West Indian Med J. 2015; 64(3):213-7.
PMID: 26426172
PMC: 4763893.
DOI: 10.7727/wimj.2014.117.
Three-month variation of plasma pentraxin 3 compared with C-reactive protein, albumin and homocysteine levels in haemodialysis patients.
Sjoberg B, Snaedal S, Stenvinkel P, Qureshi A, Heimburger O, Barany P
Clin Kidney J. 2015; 7(4):373-9.
PMID: 25852911
PMC: 4377816.
DOI: 10.1093/ckj/sfu071.
Homocysteine in renovascular complications: hydrogen sulfide is a modulator and plausible anaerobic ATP generator.
Sen U, Pushpakumar S, Amin M, Tyagi S
Nitric Oxide. 2014; 41:27-37.
PMID: 24963795
PMC: 4156889.
DOI: 10.1016/j.niox.2014.06.006.
Anethole dithiolethione lowers the homocysteine and raises the glutathione levels in solid tissues and plasma of rats: a novel non-vitamin homocysteine-lowering agent.
Giustarini D, Fanti P, Sparatore A, Matteucci E, Rossi R
Biochem Pharmacol. 2014; 89(2):246-54.
PMID: 24637238
PMC: 4142420.
DOI: 10.1016/j.bcp.2014.03.005.
Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy.
Huang Y, Gou R, Diao Y, Yin Q, Fan W, Liang Y
J Zhejiang Univ Sci B. 2014; 15(1):58-66.
PMID: 24390745
PMC: 3891119.
DOI: 10.1631/jzus.B1300109.
Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis.
Natoli J, Boer R, Nathanson B, Miller R, Chiroli S, Goodman W
BMC Nephrol. 2013; 14:88.
PMID: 23594621
PMC: 3658973.
DOI: 10.1186/1471-2369-14-88.
Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials.
Jun M, Lv J, Perkovic V, Jardine M
Ther Adv Chronic Dis. 2012; 2(4):265-78.
PMID: 23251754
PMC: 3513885.
DOI: 10.1177/2040622311401775.
Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis.
Kalantar-Zadeh K, Streja E, Molnar M, Lukowsky L, Krishnan M, Kovesdy C
Am J Epidemiol. 2012; 175(8):793-803.
PMID: 22427612
PMC: 3390012.
DOI: 10.1093/aje/kwr384.
Homocysteine is a risk factor in predialysis patients when associated with malnutrition and inflammation.
Vieira A, Baptista A, Malho A, Pinho A, Paula Silva A, Bernardo I
Int J Nephrol. 2010; 2010:957645.
PMID: 21188242
PMC: 3003985.
DOI: 10.4061/2010/957645.
Folic acid supplementation and cardiac and stroke mortality among hemodialysis patients.
Leung J, Larive B, Dwyer J, Hibberd P, Jacques P, Rand W
J Ren Nutr. 2010; 20(5):293-302.
PMID: 20303789
PMC: 2892247.
DOI: 10.1053/j.jrn.2010.01.005.
Prevalence of methylenetetrahydrofolate gene (MTHFR) C677T polymorphism among chronic hemodialysis patients and its association with cardiovascular disease: a cross-sectional analysis.
Ibrahim S, El Dessokiy O
Clin Exp Nephrol. 2009; 13(5):501-507.
PMID: 19466593
DOI: 10.1007/s10157-009-0194-2.
Mechanisms of homocysteine-induced glomerular injury and sclerosis.
Yi F, Li P
Am J Nephrol. 2007; 28(2):254-64.
PMID: 17989498
PMC: 2820346.
DOI: 10.1159/000110876.
Practical ways to deal with the high burden of cardiovascular disease in hemodialysis patients.
Lima J
Sao Paulo Med J. 2006; 124(1):36-41.
PMID: 16612461
PMC: 11060401.
DOI: 10.1590/s1516-31802006000100008.
Pharmacokinetics of N-acetylcysteine following repeated intravenous infusion in haemodialysed patients.
Soldini D, Zwahlen H, Gabutti L, Marzo A, Marone C
Eur J Clin Pharmacol. 2005; 60(12):859-64.
PMID: 15657783
DOI: 10.1007/s00228-004-0850-0.
[Atherosclerosis and uremia: signifance of non-traditional risk factors].
Horl W
Wien Klin Wochenschr. 2003; 115(7-8):220-34.
PMID: 12778774
DOI: 10.1007/BF03040320.
The Hordaland Homocysteine Studies.
Ueland P, Nygard O, Vollset S, Refsum H
Lipids. 2002; 36 Suppl:S33-9.
PMID: 11837990
DOI: 10.1007/s11745-001-0679-7.